Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 30;11:1758835919891652. doi: 10.1177/1758835919891652

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — SUCRA rank heat plot of the first-line regimens for EGFR-mutant NSCLC patients with efficacy and toxicity profile. Each sector is colored according to the SUCRA value of the corresponding treatment and outcome. The scale consists of three colors: red (0%), yellow (50%), and green (100%). Each color is associated with a different pattern. Uncolored sectors show that the underlying treatment was not included in the network meta-analyses for that particular outcome.

DCR, disease control rate; EGFR, epidermal growth factor receptor; NSCLC, nonsmall cell lung cancer; ORR, objective response rate; OS, overall survival; P, pemetrexed; PC, pemetrexed and carboplatin; PFS, progression free survival; SUCRA, surface under the cumulative ranking; TKIs, tyrosine kinase inhibitors; TRAE, treatment related adverse event.